Market Overview - The A-share market experienced a decline today, with the Shanghai Composite Index down 0.18%, the Shenzhen Component Index down 0.61%, and the ChiNext Index down 0.68% [1][2]. Sector Performance Consumer Sector - The consumer sector showed strength, particularly in the new consumption direction, with new beverage concepts seeing significant gains. Stocks such as Kweichow Moutai, Junyao Health, and Quanyangquan reached their daily limit [2]. - Within the new beverage concept, subcategories like functional drinks, probiotic drinks, yellow wine, and coconut juice are highlighted. The yellow wine concept performed strongly, with stocks like Jin Feng Jiu Ye, Gu Yue Long Shan, and Qing Fang Cheng experiencing substantial increases [2]. Pharmaceutical Sector - The pharmaceutical sector saw gains in innovative drugs and biological products, with companies like Changshan Pharmaceutical and Sanofi Genzyme experiencing significant stock price increases. Recent catalysts in the innovative drug sector are noted, with a focus on oncology, GLP-1, stem cells, and gene therapy as key areas of interest [4]. Chemical Sector - The chemical sector rallied in the afternoon, particularly in the glyphosate segment, with stocks like Zhongqi Co. and Zhongnong United reaching their daily limit. Other segments such as agricultural chemicals and chemical fibers also saw substantial increases [4]. Investment Insights - Huatai Securities indicates that the yellow wine industry has a rich heritage, with an optimized competitive landscape and upward supply-driven dynamics. The future of the yellow wine industry is expected to see a reconstruction of volume and price logic, with steady upgrades in consumption scenarios and a focus on brand cultivation by leading companies [2]. - Caitong Securities suggests focusing on three main lines in new consumption: emotional resources (pet economy, IP toys, temple economy), emotional resolution (beauty and personal care, gold and jewelry, new food and drink), and reasonable emotional release (outdoor economy, mild intoxication economy, tobacco) [3].

Group 1 - The core viewpoint is that the innovative drug sector is experiencing a significant recovery in stock prices, attracting attention from brokers for research and investment opportunities [2] - The Tianhong Innovative Drug ETF (517380) has seen a net inflow of 3.6 million yuan, with a current scale of 389 million yuan as of May 26 [1] - The Tianhong ETF is the only product that comprehensively covers the innovative drug sector across A-shares and Hong Kong stocks, with a focus on the "Hengsheng Huasheng Hong Kong Innovative Drug Selected 50" index [1] Group 2 - The innovative drug industry is entering a new cycle of value reassessment due to a combination of policy, industry, and performance factors [2] - Longjiang Securities suggests that the previous valuation methods used during the bear market may no longer be applicable, indicating a need for a re-evaluation of the valuation system for innovative drug companies [2] - There has been significant interest from brokers, with nearly 60 companies in the pharmaceutical and biotechnology sector being researched this month, highlighting the sector's attractiveness [2]

| | 证券代码：300255 证券简称：常山药业 | | | 公告编号：2025-25 | | | --- | --- | --- | --- | --- | --- | | | 河北常山生化药业股份有限公司 | | | | | | | 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 | | | | | | | 假记载、误导性陈述或重大遗漏。 | | | | | | | 河北常山生化药业股份有限公司（以下简称"公司"）近日接到控股股东高 | | | | | | | 树华先生函告，获悉高树华先生将其所持有本公司的部分股票解除质押，具体事 | | | | | | | 项如下： | | | | | | | 一、本次累计解除质押基本情况 | | | | | | | 是否为控股股东 | | | | | | | 本次解除质押 占其所持 占公司总 | | | | | | 股东名称 | 或第一大股东及 起始日 | | | 解除日 | | | 期 | 质权人 | | | | | | | 股份数量（股） 股份比例 股本比例 | | | | | | | 其一致行动人 | | | | | | | | | | 华润 ...

证券代码：300255 证券简称：常山药业 公告编号：2025-26 河北常山生化药业股份有限公司 关于为公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 河北常山生化药业股份有限公司（以下简称"公司"、"母公司"）于 2025 年 5 月 19 日召开的 2024 年度股东大会审议并通过《关于提供担保额度预计的议 案》，同意全资子公司河北常山凯库得生物技术有限公司（以下简称"凯库得"） 为母公司借款融资提供不超过 6.4 亿元的担保额度，上述额度期限自股东大会审 议通过之日起至 2025 年度股东大会之日。具体内容详见公司刊登于巨潮资讯网 的《关于提供担保额度预计的公告》（公告编号：2025-14）。 二、担保进展 2025 年 5 月 26 日，凯库得与中国民生银行股份有限公司石家庄分行（以下 简称"民生银行"）签订了《最高额抵押合同》，为在约定期限和最高额度内公 司与民生银行签订的综合授信合同项下发生的全部/部分债务提供最高额 4.5 亿 元（其中最高债权本金额 3 亿元）抵押担保。 本次担保事项在已经审议的担保额 ...

河北常山生化药业股份有限公司 关于控股股东部分股票解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300255 证券简称：常山药业 公告编号：2025-25 截至公告披露日，上述股东及其一致行动人所持质押股份情况如下： | 股东名称 | 持股数量 | 持股比例 | 累计质押 股份数量 | 占其所 持股份 | 占公司 总股本 | 已质押股份情况 已质押股 | | 未质押股份情况 | 占未质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 份限售和 | 占已质 | 未质押股 | | | | （股） | | （股） | 比例 | 比例 | 冻结、标 | 押股份 | 份限售和 | 押股份 | | | | | | | | 记数量 | 比例 | 冻结数量 | 比例 | | 高树华 | 280,644,728 | 30.54% | 149,342,900 | 53.21% | 16.25% | 0 | 0% | 0 | 0% | 注：上表"已 ...

河北常山生化药业股份有限公司投资者关系活动记录表 编号：2025-2 | | □特定对象调研 □分析师会议 □媒体采访 业绩说明会 | | --- | --- | | 投资者关系活动 | | | | □新闻发布会 □路演活动 | | 类别 | □现场参观 | | | □其他 (请文字说明其他活动内容) | | 参与单位名称及 | 参加公司 年度业绩网上说明会的投资者 2024 | | 人员姓名 | | | 时间 | 2025 年 5 月 23 日（周五）下午 15:00～17:00 | | 地点 | 投资者关系互动平台（http://ir.p5w.net） | | | 董事长兼总经理高晓东 | | 上市公司接待人 | 财务总监岳晓华 | | 员姓名 | 董事会秘书刘中英 | | | 独立董事曹德英 | | | 公司于2025年5月23日（星期五）15:00—17:00在全景网举 | | | 办了2024年度业绩说明会，与广大投资者进行互动交流，详见全 | | | 景网本次业绩说明会的交流内容。主要问题及回复如下： | | | 1．请问高总，艾本那肽一直没有获批，我们公司的营销队 | | | 伍几个月前已经准 ...

Policy Trends - Recent COVID-19 infections show a slight increase in some regions, but the clinical severity has not changed significantly according to a Chinese CDC expert [2] Drug and Device Approvals - Changshan Pharmaceutical's nadroparin calcium injection has received a drug registration certificate from Belarus, used for treating venous thromboembolism and other related conditions [3] - Shanghai Pharmaceuticals announced that its rivaroxaban tablets have received approval from the US FDA, aimed at reducing the risk of stroke and systemic embolism in non-valvular atrial fibrillation patients, among other uses [4] Capital Markets - Shanghai Kejun Pharmaceutical Technology Co., Ltd. completed a B+ round financing exceeding 100 million yuan, with funds primarily allocated for the phase III clinical development of its core product CG-0255 in the cardiovascular field [5] Industry Developments - Jingyin Pharmaceutical and CRISPR Therapeutics have formed a strategic partnership to jointly develop and commercialize a long-acting siRNA therapy for thrombotic diseases [6] - Buchang Pharmaceutical's subsidiary signed a commissioned research agreement with Fubicheng Pharmaceutical for the development of MF59 adjuvant [7] - Sanofi and Pfizer entered into a licensing agreement for a bispecific antibody product targeting PD-1 and VEGF, with Pfizer gaining exclusive rights outside mainland China [9] Public Sentiment Alerts - Jinhua Co., Ltd. reported that shareholder Xinyu Jinyu has reduced its holdings by 133,500 shares, representing 0.035765% of the company's total share capital [10] - Fosun Pharma announced the resignation of its Senior Vice President Rong Yang for personal reasons, effective May 16, 2025 [11]

宏景科技：签署5.97亿元智算项目服务合同 5月20日晚，宏景科技（301396）发布公告称，公司与Y公司近日签署了《智算项目服务合同》，由公 司按照Y公司要求向Y公司提供服务器、组网配套服务以及对服务器进行必要的改配服务，并提供算力 服务。合同总金额为5.97亿元（含税），合同期限5年。 资料显示，宏景科技成立于1997年3月，主营业务是在智慧民生、城市综合管理、智慧园区领域，为遍 布各行业的客户提供专业和系统的全流程解决方案。 所属行业：计算机–IT服务Ⅱ–IT服务Ⅲ 威孚高科：控股子公司出资2.2亿元设立合资公司 5月20日晚，威孚高科（000581）发布公告称，公司控股子公司南京威孚金宁有限公司与上海保隆汽车 科技股份有限公司的全资子公司上海保隆汽车科技（安徽）有限公司共同投资设立威孚保隆科技有限公 司，注册资本为4亿元，其中威孚金宁出资2.2亿元，占注册资本的55%。 资料显示，威孚高科成立于1988年10月，主营业务是汽车核心零部件产品的研发、生产和销售。 所属行业：汽车–汽车零部件–底盘与发动机系统 中山公用：超短期融资券和中期票据获准注册 5月20日晚，中山公用（000685）发布公告称，公司 ...

河北常山生化药业股份有限公司（以下简称"公司"）于近日收到通知，公司药 品那屈肝素钙注射液获得白俄罗斯药品管理部门签发的药品注册证书，现将相关 情况公告如下： 一、药品注册文件的基本情况 药品名称：那屈肝素钙注射液 剂型：注射剂 证券代码：300255 证券简称：常山药业 公告编号：2025-24 河北常山生化药业股份有限公司 关于那屈肝素钙注射液获得白俄罗斯药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 规格：0.4ml、0.6ml 三、对公司的影响及风险提示 本次那屈肝素钙注射液获得白俄罗斯注册批文，对公司拓展海外市场带来一 定积极影响。目前公司肝素制剂产品海外销售收入占公司营业总收入比例较低。 药品销售容易受到海外市场政策环境变化、汇率波动、市场竞争等因素的影 响，敬请广大投资者谨慎决策，注意防范投资风险。 特此公告。 河北常山生化药业股份有限公司董事会 2025 年 5 月 20 日 有效期至：2030 年 3 月 13 日 二、药品的其他相关情况 那屈肝素钙注射液主要用于治疗静脉血栓形成中度或高度危险的情况，预防 静脉血栓栓塞性疾 ...

Core Viewpoint - Changshan Pharmaceutical (300255) has received a drug registration certificate for its product, Nadroparin Calcium Injection, from the Belarusian drug regulatory authority, valid until March 13, 2030. This approval is expected to positively impact the company's expansion into overseas markets [1]. Group 1 - The drug Nadroparin Calcium Injection is primarily used for the treatment of moderate to high-risk venous thromboembolism and the prevention of venous thromboembolic diseases [1]. - The registration approval in Belarus represents a significant step for the company in terms of international market penetration [1].